SET2 Xenograft Model Service for Leukemia

The SET2 cell line offers a powerful and clinically relevant in vivo platform for investigating the progression of myeloproliferative neoplasms (MPN) toward acute myeloid leukemia (AML). As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision SET2 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your leukemia drug discovery and development pipeline.

Overview of SET2 Xenograft Model for Leukemia

The SET2 xenograft model is an essential in vivo translational system for studying the molecular drivers of disease progression in myeloid malignancies. By transplanting human SET2 cells into highly permissive, immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow infiltration, and aggressive pathological characteristics associated with the transformation from chronic MPN to acute-stage myeloid leukemia.

Biologically, the SET2 model is uniquely valuable because it harbors both JAK2V617F and DNMT3A R882H mutations, which are clinical hallmarks of high-risk myeloid disease transformation. This genetic profile allows researchers to study the synergy between cytokine signaling dysregulation and epigenetic instability. The model preserves these critical molecular features in vivo, making it an ideal platform for evaluating novel JAK inhibitors, hypomethylating agents, and combinatorial therapeutic strategies aimed at intercepting disease evolution in high-risk patients.

Cell Line Information: SET2

The SET2 cell line is derived from the peripheral blood of a patient with essential thrombocythemia that transformed into a megakaryoblastic leukemia. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable, aggressive myeloblastic/megakaryoblastic phenotype.

Our Services

Workflow of SET2 Xenograft Model Construction

• Cell Culture & Quality Control: Human SET2 cells are expanded in vitro using certified nutrient suspension media. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains) are sourced from validated vendors and undergo a dedicated acclimatization phase to stabilize baseline physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability SET2 cells is prepared in a sterile physiological buffer. The cells are inoculated in vivo into the host cohorts via intravenous tail vein injection to facilitate systemic engraftment and bone marrow homing.
• Longitudinal Growth Tracking: Disease progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid/megakaryocytic markers in the peripheral blood. Animal weight, clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts before the initiation of customized therapeutic dosing regimens.

Fig 1. SET2 Xenograft Model Construction Workflow

Case Study - SET2 Xenograft Model Development

A pre-clinical validation study was conducted using the SET2 xenograft model to evaluate the therapeutic efficacy of a novel dual-target inhibitor against JAK2 and DNMT3A-related signaling pathways. Following precision intravenous inoculation of human SET2 cells into immunodeficient mice, the animals exhibited robust, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and improved survival outcomes compared to the vehicle control, confirming the model's predictive reliability for screening high-risk leukemia therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and myeloid lineages, providing highly reproducible in vivo translational platforms for complex leukemia research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive FACS metrics and robust statistical validations.

Contact us

Accelerating your leukemia pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our SET2 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.